Immune response to an intercalated enhanced inactivated polio vaccine - Oral polio vaccine programme in Israel: Impact on the control of poliomyelitis

被引:15
|
作者
Swartz, TA [1 ]
Handsher, R
Manor, Y
Stoeckel, P
Barkay, A
Mendelson, E
Leventhal, A
机构
[1] Tel Aviv Univ, Sackler Sch Med, Dept Epidemiol & Prevent Med, IL-69978 Tel Aviv, Israel
[2] Chaim Sheba Med Ctr, Publ Hlth Labs, Cent Virol Lab, IL-52621 Tel Hashomer, Israel
[3] Assoc Aide Med Prevent, F-92430 Marnes La Coquette, France
[4] No Publ Hlth Dist, IL-17000 Nazareth, Israel
[5] Minist Hlth, Publ Hlth Serv, IL-90100 Jerusalem, Israel
关键词
EIPV/OPV combined vaccination; poliovirus vaccine efficacy; poliomyelitis control;
D O I
10.1016/S0264-410X(98)00071-1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A combined enhanced inactivated polio vaccine (EIPV) and oral polio vaccine (OPV) programme was introduced in Israel in 1990, with the purpose of providing a solution to the persistent polio morbidity bz spite of a 30 year long OPV programme. The schedule comprised two noses of EIPV administered at the age of 2 and 4 months, intercalated with two doses of OPV at 4 and 6 months, followed by a reinforcing dose with the two vaccines simultaneously administered at 12 months. The 5-year evaluation of the programme included: the assessment of clinical suspicions of polio, early immune response in successive cohorts administered the new schedule, dynamics of the immune profile in a cohort followed rip to the age of 5 and monitoring of wild poliovirus excretion in sewage specimens collected in25 permanent sites throughout Israel as well as front the Palestinian Authority. No paralytic polio cases associated with a wild or vaccinal poliovirus strain were defected since the introduction of the programme. At the age of 4 months, one week after administration of the second EIPV and first OPV nose, 100% seropositivity and high geometric mean titres (GMTs) of neutralizing antibody (NA) to the three vaccinal and to the wild poliovirus type I, responsible for the 1988 polio outbreak, were observed. No change in percent of seropositivity occurred between the age of 6 and 12 months. Thirty days after the IPV and OPV reinforcing noses, GMTs to each of the foul. poliovirus strains were greater than or equal to 3037. Up to the age of 5, the seropositivity was unchanged. After a 2.5-10-fold decline in the first year following the completion of the programme, GMTs to the three vaccinal and the wild poliovirus strain levelled off at rather high values, considered protective. Between 1990 and 1995, 16 wild poliovirus type 1 strains were isolated in three separate episodes in Gaza Strip sewage and once only in one Israeli site very close to Gaza City. The rapidly established high and persistent NA titre to the vaccinal and wild poliovirus strains and the presence of immunological memory are indicative of high individual protection throughout the first 5 years of life. The only one-time introduction, without circulation, of a wild poliovirus strain in a single Israeli settlement suggests community protection. The intercalated programme offers a contribution to polio el eradication by providing a solution to the primary and secondary failure associated with OPV, as well as to the control of vaccine-associated paralytic poliomyelitis. (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2090 / 2095
页数:6
相关论文
共 50 条
  • [41] Vaccine-associated paralytic poliomyelitis: A case report of flaccid monoparesis after oral polio vaccine
    Kim, Sun Jun
    Kim, Sung Han
    Jee, Young Mee
    Kim, Jung Soo
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2007, 22 (02) : 362 - 364
  • [42] Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine-only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants
    Brickley, Elizabeth B.
    Wieland-Alter, Wendy
    Connor, Ruth, I
    Ackerman, Margaret E.
    Boesch, Austin W.
    Arita, Minetaro
    Weldon, William C.
    O'Ryan, Miguel G.
    Bandyopadhyay, Ananda S.
    Wright, Peter F.
    CLINICAL INFECTIOUS DISEASES, 2018, 67 : S42 - S50
  • [43] Oral Polio Vaccine Influences the Immune Response to BCG Vaccination. A Natural Experiment
    Sartono, Erliyani
    Lisse, Ida M.
    Terveer, Elisabeth M.
    van de Sande, Paula J. M.
    Whittle, Hilton
    Fisker, Ane B.
    Roth, Adam
    Aaby, Peter
    Yazdanbakhsh, Maria
    Benn, Christine S.
    PLOS ONE, 2010, 5 (05):
  • [44] Vaccine Poliovirus Shedding and Immune Response to Oral Polio Vaccine in HIV-Infected and -Uninfected Zimbabwean Infants
    Troy, Stephanie B.
    Musingwini, Georgina
    Halpern, Meira S.
    Huang, ChunHong
    Stranix-Chibanda, Lynda
    Kouiavskaia, Diana
    Shetty, Avinash K.
    Chumakov, Konstantin
    Nathoo, Kusum
    Maldonado, Yvonne A.
    JOURNAL OF INFECTIOUS DISEASES, 2013, 208 (04): : 672 - 678
  • [45] Experience With Inactivated Polio Vaccine Introduction and the "Switch" From Trivalent to Bivalent Oral Polio Vaccine in the World Health Organization's Western Pacific Region
    Gurung, Santosh
    Harris, Jennifer B.
    Eltayeb, Abu Obeida
    Hampton, Lee M.
    Diorditsa, Sergey
    Avagyan, Tigran
    William Schluter, W.
    JOURNAL OF INFECTIOUS DISEASES, 2017, 216 : S101 - S108
  • [46] IMMUNE-RESPONSE OF INFANTS IN TROPICS TO INJECTABLE POLIO VACCINE
    ARYA, SC
    BRITISH MEDICAL JOURNAL, 1982, 285 (6344): : 818 - 818
  • [47] IMMUNE-RESPONSE OF INFANTS IN TROPICS TO INJECTABLE POLIO VACCINE
    KRISHNAN, R
    JADHAV, M
    SELVAKUMAR, R
    JOHN, TJ
    BRITISH MEDICAL JOURNAL, 1982, 284 (6310): : 164 - 164
  • [48] Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine
    Brickley, Elizabeth B.
    Strauch, Carolyn B.
    Wieland-Alter, Wendy F.
    Connor, Ruth I.
    Lin, Shu
    Weiner, Joshua A.
    Ackerman, Margaret E.
    Arita, Minetaro
    Oberste, M. Steven
    Weldon, William C.
    Saez-Llorens, Xavier
    Bandyopadhyay, Ananda S.
    Wright, Peter F.
    JOURNAL OF INFECTIOUS DISEASES, 2018, 217 (03): : 371 - 380
  • [49] POLIOMYELITIS CONTROL BY ANNUAL IMMUNIZATION CAMPAIGNS WITH ORAL POLIO-VIRUS VACCINE IN A RURAL AREA OF INDIA
    KUMAR, R
    KUMAR, V
    TROPICAL AND GEOGRAPHICAL MEDICINE, 1991, 43 (1-2): : 215 - 219
  • [50] Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame
    Parker, Edward P. K.
    Molodecky, Natalie A.
    Pons-Salort, Margarita
    O'Reilly, Kathleen M.
    Grassly, Nicholas C.
    EXPERT REVIEW OF VACCINES, 2015, 14 (08) : 1113 - 1123